2. Protein Tyrosine Kinase/RTK Apoptosis
  3. BMX Kinase Apoptosis
  4. IHMT-15137

IHMT-15137 is a BMX inhibitor with an IC50 of 26.97 nM. IHMT-15137 covalently binds to BMX Cys496 within the ATP-binding pocket, inhibits BMX phosphorylation at Tyr566, and disrupts the BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 signaling axis. IHMT-15137 reduces E2F1 protein stability via decreased Ser332/337 phosphorylation, increased ubiquitination, and ubiquitin-proteasome pathway degradation. IHMT-15137 induces cell cycle arrest, apoptosis, DNA damage, and suppresses cell migration and invasion. IHMT-15137 can be used for the research of small cell lung cancer.

For research use only. We do not sell to patients.

IHMT-15137

IHMT-15137 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

IHMT-15137 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IHMT-15137 is a BMX inhibitor with an IC50 of 26.97 nM. IHMT-15137 covalently binds to BMX Cys496 within the ATP-binding pocket, inhibits BMX phosphorylation at Tyr566, and disrupts the BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 signaling axis. IHMT-15137 reduces E2F1 protein stability via decreased Ser332/337 phosphorylation, increased ubiquitination, and ubiquitin-proteasome pathway degradation. IHMT-15137 induces cell cycle arrest, apoptosis, DNA damage, and suppresses cell migration and invasion. IHMT-15137 can be used for the research of small cell lung cancer[1].

In Vitro

IHMT-15137 (3 μM; 24-168 h) synergizes with cisplatin (5-30 μM) to reduce viability, induce S-phase cell cycle arrest, suppress proliferation, promote apoptosis, increase DNA damage, and disrupt the BMX-ERK1/2-Cyclin D1-E2F1 signaling axis in SCLC patient-derived cells C23084 and LUC22009[1].
IHMT-15137 potentiates the cytotoxic and antiproliferative effects of Cisplatin + Etoposide (HY-13629) chemotherapy in SCLC patient-derived cells C23084 and LUC22009[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IHMT-15137 Related Antibodies

Cell Cycle Analysis[1]

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 3 μM; 3 μM plus 5 μM Cisplatin
Incubation Time: 48 h
Result: Induced S-phase cell cycle arrest.

Cell Proliferation Assay[1]

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 3 μM; 3 μM plus 5 μM Cisplatin
Incubation Time: 14 days
Result: Suppressed cell proliferation compared with DMSO group.

Western Blot Analysis[1]

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 10 μM; 10 μM plus 30 μM Cisplatin
Incubation Time: 24 h
Result: Enhanced apoptosis (cleaved PARP and cleaved caspase-3) and significantly increased DNA damage (γ-H2AX) in the treated groups compared with the monotherapies.

Western Blot Analysis[1]

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 3 μM; 3 μM plus 30 μM Cisplatin
Incubation Time: 24 h
Result: Potentiated the effects of Cisplatin by modulating the ERK1/2-Cyclin D1/CDK4/6 signaling axis and promoting the degradation of E2F1.
In Vivo

IHMT-15137 (100 mg/kg; i.p.) in combination with Cisplatin and Etoposide induces 60.1% tumor growth inhibition, enhances apoptosis, and suppresses proliferation in H69AR SCLC xenografts without significant toxicity[1].
IHMT-15137 (100 mg/kg; i.p.) in combination with Cisplatin and Etoposide induces 69.0% tumor growth inhibition, enhances apoptosis, and suppresses proliferation in H446DDPR SCLC xenografts without significant toxicity[1].
IHMT-15137 (100 mg/kg; i.p.) in combination with Cisplatin and Etoposide induces 59.8% tumor growth inhibition, enhances apoptosis, and suppresses proliferation in SCLC patient-derived xenografts without significant toxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NCG mice (female, 6 weeks old, subcutaneous xenograft model implanted with chemoresistant H69AR cells)[1]
Dosage: 100 mg/kg; 100 mg/kg plus 2 mg/kg Cisplatin plus 16 mg/kg Etoposide
Administration: i.p.
Result: Achieved 60.1% tumor growth inhibition (TGI).
Reduced final mean tumor weight to 0.96 g compared to vehicle control (2.46 g).
Suppressed chemotherapy-induced increases in tumor tissue levels of p-BMX (Tyr566), p-ERK1/2 (Thr202/Tyr204), Cyclin D1, p-E2F1 (Ser332), and p-E2F1 (Ser337).
Increased tumor apoptosis (TUNEL-positive cells) compared to monotherapies.
Reduced tumor proliferation (Ki-67-positive cells) compared to monotherapies.
Caused no significant body weight loss.
Animal Model: NCG mice (female, 6 weeks old, subcutaneous xenograft model implanted with chemoresistant H446DDPR cells)[1]
Dosage: 100 mg/kg; 100 mg/kg plus 2 mg/kg Cisplatin plus 16 mg/kg Etoposide
Administration: i.p.
Result: Achieved 69.0% tumor growth inhibition (TGI).
Reduced final mean tumor weight to 0.78 g compared to vehicle control (2.52 g).
Suppressed chemotherapy-induced increases in tumor tissue levels of p-BMX (Tyr566), p-ERK1/2 (Thr202/Tyr204), Cyclin D1, p-E2F1 (Ser332), and p-E2F1 (Ser337).
Increased tumor apoptosis (TUNEL-positive cells) compared to monotherapies.
Reduced tumor proliferation (Ki-67-positive cells) compared to monotherapies.
Caused no significant body weight loss.
Animal Model: NCG mice (female, 6 weeks old, subcutaneous patient-derived xenograft model implanted with PDC C23084 cells)[1]
Dosage: 100 mg/kg; 100 mg/kg plus 2 mg/kg Cisplatin plus 16 mg/kg Etoposide
Administration: i.p.
Result: Achieved 59.8% tumor growth inhibition (TGI).
Reduced final mean tumor weight to 0.39 g compared to vehicle control (0.97 g).
Suppressed chemotherapy-induced increases in tumor tissue levels of p-BMX (Tyr566), p-ERK1/2 (Thr202/Tyr204), Cyclin D1, p-E2F1 (Ser332), and p-E2F1 (Ser337).
Increased levels of cleaved PARP and cleaved caspase-3 (apoptosis markers).
Increased tumor apoptosis (TUNEL-positive cells) compared to monotherapies.
Reduced tumor proliferation (Ki-67-positive cells) compared to monotherapies.
Caused no significant body weight loss.
Molecular Weight

446.43

Formula

C21H21F3N6O2
SMILES

FC(F)(F)C1=CC=C(NC(C2=NNC=C2NC(CC3CN(C(C=C)=O)CCC3)=O)=N4)C4=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IHMT-15137 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IHMT-15137IHMT15137IHMT 15137BMX KinaseApoptosisCyclin D1E2F1Tyr566small cell lung cancerBMXCys496SCLC patient-derived cellsCDK4/6H69AR SCLC xenograftsERK1/2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IHMT-15137
Cat. No.:
HY-182902
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.